No insider purchase over the last 90 days. The latest, by 지베이스, was filed 16 Jul 2026.
Aprogen Medicines Inc.: what insiders have been doing
Aprogen Medicines Inc., classified in the Industrials sector, is a listed company. Its insiders report their share dealings to DART (FSS). Between 6 November 2025 and 6 November 2026, 11 insiders published 31 filings.
Open-market activity splits into 9 purchases totalling €1.2M and 16 sales totalling €3.4M; 3 insiders sit on the buying side and 10 insiders on the selling side. No amount is published for 21 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 2 major shareholders and 1 chief executive. 지베이스 filed the largest sale, €1.9M, on 15 May 2026, which represents 6.4% of the company's market value.
The last purchase on record was published on 16 July 2026, which is 116 days ago. The median gap between a trade and its publication by DART (FSS) is 4 days. Until a filing is published, the market cannot know about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (2,658 companies, median 7 filings), a count of 31 filings is above the norm. The full history, which starts in 2021, counts 22 purchases against 68 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Auroora Yhtiöt Oyj and MBB SE. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySale+5 other insiders
Since the insiders bought
- -19.8%Entry ₩2,185 · Close 05 Nov 2026 ₩1,752
- -28.9%Entry ₩2,465 · Close 05 Nov 2026 ₩1,752
- -66.3%Entry ₩5,200 · Close 05 Nov 2026 ₩1,752
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 7,994,497 sharesKRXDART:20260716000617Canonical exit: 14 Oct 2026 (T+90)
- 851,013 sharesKRXDART:20260701000616Canonical exit: 29 Sept 2026 (T+90)
- 851,012 sharesKRXDART:20260626000522Canonical exit: 24 Sept 2026 (T+90)
- 3,655,335 sharesKRXDART:20260619000506Canonical exit: 17 Sept 2026 (T+90)
- 703,400 sharesKRXDART:20260610000429
- 4,487,530 sharesKRXDART:20260529001831Canonical exit: 27 Aug 2026 (T+90)
- ●Executives0DART
- 703,399 shares6.36% mcap41.7% of flowKRXDART:20260515002031
- 19,390,690 shares100.0% of flowKRXDART:20260512000504
- 74,895 sharesShareKRXDART:20260511000570Canonical exit: 30 Jul 2026 (T+90)
- 468,932 shares3.90% mcap27.3% of flowKRXDART:20260508000803
- 119,580 sharesShareKRXDART:20260508000891
- 49,825 sharesShareKRXDART:20260508000916
- 94,668 sharesShareKRXDART:20260508000844
25 of 158 declarations
About Aprogen Medicines Inc.
Aprogen is a company operating in the industrial sector, listed on the XKRX. It focuses on the development and production of biopharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
